Abiopharma

🔍 Cain Wettan Keeley M (Executive)

Company: GILEAD SCIENCES, INC. (GILD)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 6,002 shares of Common Stock (Direct)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,362.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,908 shares of Common Stock at $133.06 per share (Direct)
  Date: 2026-08-10 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,454.00 | transaction_form_type: 4
• Sold 6,002 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,995.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• F2: The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.